Valuation : Moderna, Inc.

Market Cap 56.03B 48.24B 45.3B 41.35B 77.68B 5,331B 78.23B 537B 209B 2,703B 210B 206B 8,951B P/E 2026 *
-16.4x
P/E 2027 * -28.6x
Enterprise Value 52.38B 45.1B 42.35B 38.66B 72.62B 4,984B 73.14B 502B 195B 2,527B 197B 192B 8,368B EV / Sales 2026 *
25x
EV / Sales 2027 * 22x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-1.74%
1 week+1.04%
Current month+156.00%
1 month+156.00%
3 months+204.69%
6 months+181.64%
Current year+375.89%
1 week 133.33
Extreme 133.33
161.37
1 month 52.66
Extreme 52.6601
176.66
Current year 29.81
Extreme 29.81
176.66
1 year 22.28
Extreme 22.28
176.66
3 years 22.28
Extreme 22.28
176.66
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
06/08/26 Exercice

Chief Executive Officer

504,938 0.1273%
15/07/26 Exercice

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%+1.04%+480.16%+24.12% 55.09B
+0.62%-3.55%+38.27%-3.32% 79.3B
+1.17%+2.66%-17.43%-36.53% 59.21B
+2.15%-2.13%-1.37%+30.77% 49.86B
-0.55%-2.14%+8.08%+160.02% 47.9B
-0.85%-0.67%+55.16%-18.97% 32.28B
-0.92%-3.72%+43.31%+90.95% 25.21B
-1.35%+2.71%-3.04%+191.17% 23.87B
-3.52%-0.49%+58.94%+112.57% 16.89B
-3.91%-3.91%-8.84%+773.77% 16.17B
Average -0.91%-1.01%+65.32%+132.46% 40.58B
Weighted average by Cap. -0.26%-1.87%+79.91%+70.87%

Financials

2026 *2027 *
Net sales 2.1B 1.81B 1.7B 1.55B 2.91B 199B 2.93B 20.09B 7.81B 101B 7.87B 7.7B 335B 2.44B 2.1B 1.98B 1.8B 3.39B 232B 3.41B 23.41B 9.11B 118B 9.17B 8.97B 390B
Net income -3.31B -2.85B -2.68B -2.44B -4.59B -315B -4.63B -31.73B -12.35B -160B -12.44B -12.17B -529B -1.94B -1.67B -1.57B -1.43B -2.69B -185B -2.71B -18.6B -7.24B -93.66B -7.29B -7.13B -310B
Net Debt -3.65B -3.14B -2.95B -2.69B -5.06B -347B -5.1B -34.96B -13.6B -176B -13.7B -13.4B -583B -2.19B -1.89B -1.77B -1.62B -3.04B -209B -3.06B -21.01B -8.18B -106B -8.24B -8.06B -350B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
31/08/26 US$140.34 +1.70% 18,549,029
28/08/26 US$137.99 -3.35% 25,820,563
27/08/26 US$142.77 -4.60% 24,993,236
26/08/26 US$149.66 -5.77% 22,009,462
25/08/26 US$158.83 +14.36% 49,225,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
140.34USD
Average target price
112.56USD
Spread / Average Target
-19.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock